Advertisement
Home »

Novel Fc-enhanced CTLA-4 Inhibitor Scores in Colorectal Cancer

Jan 27, 2023

REFERENCES & ADDITIONAL READING

  1. El-Khoueiry AB, et al. Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC). Late-breaking abstract 8, ASCO GI 2023, 19–21 January, San Francisco, CA, USA.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


EXPLORE MORE

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement